Artificial intelligence (AI) software developer RapidAI has received clearance from the U.S. Food and Drug Administration (FDA) for a new algorithm designed to help physicians determine the extent of an intracerebral hemorrhage (ICH).
Called Rapid Hyperdensity, the algorithm analyzes noncontrast CT scans to assess the volume of hyperdense tissue in the brain. RapidAI believes the software can give healthcare providers at hospitals and mobile stroke units additional information that will help them triage patients with suspected ICH and make appropriate transfer decisions.
The application can perform automated detection of intracranial hyperdensities that are less than 1 ml, can quickly identify hyperdense volumes, and can send results via the company's Rapid mobile app, PACS workstation, or email, according to the company.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
